<DOC>
	<DOCNO>NCT00979004</DOCNO>
	<brief_summary>Subjects epilepsy document photoparoxysmal response intermittent photic stimulation ( IPS ) participate . Four subject enrol dose level receive single dose placebo single dose ICA-105665 study , follow intermittent photic stimulation . The effect ICA-105665 photoparoxysmal electroencephalography ( EEG ) response group review dose select subsequent group subject .</brief_summary>
	<brief_title>A Study Investigate Effect ICA-105665 Photosensitive Epilepsy Patients</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>A diagnosis history epilepsy 02 concurrent antiepileptic drug . On stable dose current AED ( ) 4 week prior Screening Visit . Must good health ( exception epilepsy ) , determine Primary Investigator via medical history , physical examination , screen laboratory investigation . A body mass index ( BMI ) 18 35 . Able willing give write informed consent prior participation study . A reproducible IPSinduced photoparoxysmal EEG response ( PPR ) least 3 point frequency assessment scale least one eye condition change 3 frequency 2 repeat measurement record Screening Visit . History nonepileptic seizure ( metabolic , structural , pseudoseizures ) . History status epilepticus antiepileptic medication . The etiology seizure due follow ; progressive degenerative disease , metabolic illness , active infection , demyelination , drug , alcohol . The subject use benzodiazepine ( oral , intramuscular , suppository ) escape medication within past 6 month . The subject take investigational medication within 30 day prior Day 1 . Women pregnant lactating . An active Central Nervous System ( CNS ) infection , demyelinate disease , degenerative neurological disease CNS disease deem progressive course study may confound interpretation study result . The subject clinically significant ( e.g. , cancerous , unstable , progressive , functionally disable , infectious ) medical condition would interfere ability complete study might interfere absorption , distribution , metabolism , and/or excretion drug . Subjects impaired hepatic function [ ALT ( Alanine aminotransferase ) , AST ( Aspartate aminotransferase ) =3 time upper limit normal ] clinically significant laboratory abnormality , opinion investigator , would increase risk participation interfere interpretatio study result . History alcoholism , drug abuse , drug addiction within last 12 month . Clinically significant psychiatric illness , psychological behavioral problem , opinion investigator would interfere subject 's ability participate study OR subject receive therapy neuroleptic drug . Subject experience clinical seizure IPS procedure perform screening period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Photosensitivity</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
</DOC>